Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06565936

DPA-714 and FDG PET/MRI in Depression

Sponsor: The First Affiliated Hospital of Dalian Medical University

View on ClinicalTrials.gov

Summary

Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \[18F\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms. We hypothesize that microglial activation in depression, especially in major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions, will show higher TSPO levels and increased glucose metabolism compared to the control group.

Official title: Clinical Application of DPA-714 and FDG PET/MRI Imaging in Patients With Depression

Key Details

Gender

All

Age Range

35 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-08-23

Completion Date

2026-12

Last Updated

2024-11-12

Healthy Volunteers

Yes

Conditions

Depression

Interventions

RADIATION

PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG

Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

Inclusion Criteria: 1. For all groups : * No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination * MMSE≥24 points，MOCA≥26 points * No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks * Patients with diabetes had fasting controlled below 9.0mmol/L before the examination * Volunteer to participate in the study and sign the informed consent 2. For Recurrent depression patients: * Meet the Diagnostic criteria for recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * Age 35-85 years old, gender is not limited * HAMD≥8 points 3. For first episode depression Patients: * Gender, age and education level were matched with the recurrent depression group * Meet the Diagnostic criteria for the first episode of depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * HAMD≥8 points 4. For controls: * Healthy people undergoing "DPA-714 or FDG imaging PET/MRI" physical examination in PET/CT room of our hospital * Gender and education level were consistent with both the recurrent depression group and the first-episode depression group * never used any psychotropic drugs * HAMD\<8 points；HAMA\<7 points Exclusion Criteria(for all groups): * Have a history of organic mental disorders or other mental disorders * A family history of hereditary diseases * Persons with mental retardation or dementia * A history of psychoactive substance abuse * Can not cooperate with/complete the psychological examination scale * Previously found serious physical diseases (heart, brain, liver, lung and kidney) * MRI contraindications, abnormalities found in head CT or MRI * A history of drug or alcohol abuse * Have a history of metabolic diseases such as hyperthyroidism, hypothyroidism,and rheumatic diseases * are in the state of pregnancy or breastfeeding

Locations (1)

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China